Effect of FHIT gene replacement on growth, cell cycle and apoptosis in pancreatic cancer cells

Pancreatology

Volumn 3, Issue 4, 2003, Pages 293-302

  Gopalakrishnan, Velliyur K ^a   Banerjee, Abhijit G ^a   Vishwanatha, Jamboor K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cell cycle; FHIT gene; Pancreatic cancer; Tumor growth

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D3; FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL X; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CANCER CELL; CANCER GROWTH; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; COLORIMETRY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE CONTROL; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; PANCREAS TUMOR; PATHOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

EID: 0042674157     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000071767     Document Type: Article

References (38)

1. American Cancer Society: Cancer Facts and Figures. ACS, Atlanta, 2001.
2. Hilgers W, Kern SE: Molecular genetic basis of pancreatic carcinoma. Genes Chromosomes Cancer 1999;26:1-12.
3. Regine WF, John WJ, Mohiuddin M: Adjuvant therapy for pancreatic cancer: Current status. Front Biosci 1998;3:E186-E192.
4. Blaszkowsky L: Treatment of advanced and metastatic pancreatic cancer. Front Biosci 1998;3:E214-E225.
5. Lorenz M, Heinrich S, Staib-sebler E, Kohne C-H, Wils J, Nordlinger B, Encke A: Regional chemotherapy in the treatment of advanced pancreatic cancer-it is relevant. Eur J Cancer 2000;36:957-965.
6. Rosenberg L: Pancreatic cancer: A review of emerging therapies. Drugs 2000;59:1071-1089.
7. Perugini RA, Mcdade TP, Vittimberga FJ Jr, Callery MP: The molecular and cellular biology of pancreatic cancer. Crit Rev Eukaryotic Gene Expression 1998;8:377-393.
8. Simon B, Bartsch D, Barth P, Prasnikar N, Munch K, Blum A, Arnold R, Goke B: Frequent abnormalities of the putative suppressor gene Fhitat 3p14.2 in pancreatic carcinoma cell lines. Cancer Res 1998;58:1583-1587.
9. Fiess H, Kleeff J, Kore M, Buchler MW: Molecular aspects of pancreatic cancer and future perspectives. Dig Surg 1999;16:281-290.
10. Ohta M, Inoue M, Cottiecelli MG, Kastury K, Baffa R, Palazzo J, Siprashvilli Z, Mori M, McCue P, Druck T, Croce CM, Huebner K: The Fhit gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive cancers. Cell 1996;587-597.
11. Barnes LD, Garrison PN, Siprashvilli Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K: FHIT a putative tumor suppressor in human is a dinucleotide 5′5‴-p1,p3 triphosphate hydrolase. Biochemistry 1996;35:11529-11535.
12. Sozzi G,Veronese ML, Negrini M, Buffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, DeGregorio L, Pastorino L, Pastorino V, Pierotti MA, Ohta M, Huebner K, Croce CM: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
13. Negrini M, Manaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM: The FHIT gene at 3p14.2 in abnormal in breast carcinomas. Cancer Res 1996:56:3173-3179.
14. Man S, Ellis IO, Sibbering M, Blamey RW, Brook JD: High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 1996;56:5484-5489.
15. Druck T, Hadaczek P, Fu TB, Ohta M, Siiprashvilli Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM, Huebner K: Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997;57:504-512.
16. Siprashvilli Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eeyomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K: Replacement of FHIT in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997;94:13771-13776.
17. 4-tetra phosphate (Ap4A) asymmetrical hydrolase: Sequence similarity with the histidine triad (HIT) protein family. Biochem J 1995;312:925-932.
18. Robinson AK, De la Pena CE, Barnes LD: Isolation and characterization of diadenosine tetraphosphate(Ap4A)hydrolase from Schizosaccharomyces pombe. Biochim Biophys Acta 1993;1161:139-148.
19. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA: Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector mediated fragile histidine triad (FHIT) gene overexpression.Cancer Res 1999;59:3333-3339.
20. Guo Z, Johansson SL, Rhim JS, Vishwanatha JK: Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model. Prostate 2000;43:101-110.
21. Guo Z, Vishwanatha JK: Effect of regulated expression of the fragile histidine triad gene on cell cycle and proliferation. Mol Cell Biochem 2000;204:83-88.
22. Mossman T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
23. Telford WG, King LE, Fraker PJ: Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif 1991;24:447-459.
24. Golebiowski F, Kowara R, Pawelczyk T: Distribution of fhit protein in rat tissues and its intracellular localization. Mol Cell Biochem 2001;226:49-55.
25. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC, Lane DP, Lemoine NR: Abnormalities of p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-1082.
26. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant C-K-ras gene. Cell 1988;53:549-554.
27. Korc M: Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41.
28. Brenner C, Garrison P, Gilmour J, Peisach D, Ringe D, Petsko GA, Lowenstein JM: Crystal structures of HINT demonstrate that histidine triad proteins are Gal T-related nucleotide binding proteins. Nat Struct Biol 1997;4:231-238.
29. Sorio C, Baron A, Orlandini S, Zamboni G, Pederzoli P, Huebner K, Scarpa A: The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 1999;59:1308-1314.
30. Ebert MP, Hernberg S, Fei G, Sokolowski A, Schulz HU, Lippert H, Malferheiner P: Induction and expression of cyclin D3 in human pancreatic cancer. J Cancer Res Clin Oncol 2001;127:449-454.
31. Mendelsohn AR, Hamer JD, Wang ZB, Brent R: Cyclin D3 activates caspase 2, connecting cell proliferation with cell death. Proc Natl Acad Sci USA 2002;99:6871-6876.
32. Konishi Y, Lehtinen M, Donovan N, Bonni A: Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell 2002;9:1005-1016.
33. Levine AJ: p53 the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
34. Roth JA, Cristiano RJ: Gene therapy for cancer: What have we done and where we are going? Rev J Natl Cancer Inst 1997;89:857-862.
35. Naik P, Karrim J, Hanahan D: This rise and fall of apoptosis during multistage tumorigenesis: Down modulation contributes to tumor progression from angiogenic progenitors. Genes Dev 1996;10:2105-2116.
36. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, Croce CM: Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001;61:4827-4836.
37. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA, Sozzi G: The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999;96:8489-8492.
38. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G: Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002;99:3615-3620.